Literature DB >> 24221578

Expression of Ets-1 and FOXP3 mRNA in CD4(+)CD25 (+) T regulatory cells from patients with systemic lupus erythematosus.

Nan Xiang1, Xiang-Pei Li, Xiao-Mei Li, Guo-Sheng Wang, Jin-Hui Tao, Hai-Feng Pan, Xuan Fang, Qian Ma, Ning Yu.   

Abstract

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with complex genetic predisposing factors involved. Ets-1 transcription factor plays an important role in the suppressive activity of CD4(+)CD25(+) Treg cells and stable expression of FOXP3. To find its potential role in the pathogenesis of SLE, we investigate the mRNA expression of Ets-1 and FOXP3 mRNA in CD4(+)CD25(+) Treg cells from patients with SLE. Real-time transcription-polymerase chain reaction analysis was used to determine the expression of Ets-1 and FOXP3 mRNA in CD4(+)CD25(+) Treg cells from 36 patients with SLE and 18 sex-and-age-matched healthy controls. The Ets-1 mRNA expression level was decreased in patients with SLE [0.225 (0.135, 0.337)] than healthy controls [0.528 (0.303, 0.681)] (P < 0.001). The expression levels of FOXP3 mRNA were lower in SLE patients [0.608 (0.272, 1.164)] than healthy controls [0.919 (0.690, 1.223)], but the difference was not significant (P = 0.106). Significant reduction in Ets-1 and FOXP3 expression was also found in new-onset SLE subgroup when compared with healthy controls (P < 0.001). The level of Ets-1 and FOXP3 mRNA was not significantly different in hyperactive and lower active SLE group when compared with inactive SLE group, respectively (P > 0.05). There were no significant differences between SLE with lupus nephritis (LN) and SLE without LN either (P > 0.05). Associations of Ets-1 and FOXP3 mRNA expression levels with major clinical and laboratory parameters of SLE patients were also analyzed. However, no significant association was found. Significant positive correlation was found between Ets-1 and FOXP3 mRNA expression in CD4(+)CD25(+) Treg cells from SLE patients (r = 0.698, P < 0.001). Our results found that the expression levels of Ets-1 mRNA were decreased in SLE patients and Ets-1 expression was positively correlated with the expression of FOXP3. It indicated that Ets-1 may play an important role in the stable expression of FOXP3 in CD4(+)CD25(+) Treg cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24221578     DOI: 10.1007/s10238-013-0263-4

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  30 in total

1.  The development of early and mature B cells is impaired in mice deficient for the Ets-1 transcription factor.

Authors:  Stéphanie Eyquem; Karine Chemin; Magali Fasseu; Martine Chopin; François Sigaux; Ana Cumano; Jean-Christophe Bories
Journal:  Eur J Immunol       Date:  2004-11       Impact factor: 5.532

2.  Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells.

Authors:  Hyung W Lim; Peter Hillsamer; Allison H Banham; Chang H Kim
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

3.  Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus.

Authors:  Xavier Valencia; Cheryl Yarboro; Gabor Illei; Peter E Lipsky
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

4.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

5.  Inverse correlation between CD4+ regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus.

Authors:  Jyh-Hong Lee; Li-Chieh Wang; Yu-Tsan Lin; Yao-Hsu Yang; Dong-Tsamn Lin; Bor-Luen Chiang
Journal:  Immunology       Date:  2006-02       Impact factor: 7.397

Review 6.  Regulatory T-cell physiology and application to treat autoimmunity.

Authors:  Qizhi Tang; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2006-08       Impact factor: 12.988

7.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

8.  The mouse and human Fli1 genes are similarly regulated by Ets factors in T cells.

Authors:  J L Svenson; K Chike-Harris; M Y Amria; T K Nowling
Journal:  Genes Immun       Date:  2009-10-15       Impact factor: 2.676

Review 9.  Control of autoimmunity by naturally arising regulatory CD4+ T cells.

Authors:  Shohei Hori; Takeshi Takahashi; Shimon Sakaguchi
Journal:  Adv Immunol       Date:  2003       Impact factor: 3.543

10.  DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells.

Authors:  Udo Baron; Stefan Floess; Georg Wieczorek; Katrin Baumann; Andreas Grützkau; Jun Dong; Andreas Thiel; Tina J Boeld; Petra Hoffmann; Matthias Edinger; Ivana Türbachova; Alf Hamann; Sven Olek; Jochen Huehn
Journal:  Eur J Immunol       Date:  2007-09       Impact factor: 5.532

View more
  14 in total

1.  Negative Correlation Between miR-326 and Ets-1 in Regulatory T Cells from new-Onset SLE Patients.

Authors:  Xiao-Ge Sun; Jin-Hui Tao; Nan Xiang; Xiao-Mei Li; Guo-Sheng Wang; Xuan Fang; Chao Dai; Min Zhang; Zhu Chen; Xiang-Pei Li
Journal:  Inflammation       Date:  2016-04       Impact factor: 4.092

2.  A balance between B cell receptor and inhibitory receptor signaling controls plasma cell differentiation by maintaining optimal Ets1 levels.

Authors:  Anne B Satterthwaite; Wei Luo; Jessica Mayeux; Toni Gutierrez; Lisa Russell; Andrew Getahun; Jennifer Müller; Thomas Tedder; Jane Parnes; Robert Rickert; Lars Nitschke; John Cambier; Lee Ann Garrett-Sinha
Journal:  J Immunol       Date:  2014-06-13       Impact factor: 5.422

3.  The Role of the Transcription Factor Ets1 in Lupus and Other Autoimmune Diseases.

Authors:  Lee Ann Garrett-Sinha; Alyssa Kearly; Anne B Satterthwaite
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

4.  Ets1 suppresses atopic dermatitis by suppressing pathogenic T cell responses.

Authors:  Choong-Gu Lee; Ho-Keun Kwon; Hyeji Kang; Young Kim; Jong Hee Nam; Young Ho Won; Sunhee Park; Taemook Kim; Keunsoo Kang; Dipayan Rudra; Chang-Duk Jun; Zee Yong Park; Sin-Hyeog Im
Journal:  JCI Insight       Date:  2019-03-07

5.  Genetic Interaction between Lyn, Ets1, and Btk in the Control of Antibody Levels.

Authors:  Jessica Mayeux; Brian Skaug; Wei Luo; Lisa M Russell; Shinu John; Prontip Saelee; Hansaa Abbasi; Quan-Zhen Li; Lee Ann Garrett-Sinha; Anne B Satterthwaite
Journal:  J Immunol       Date:  2015-07-24       Impact factor: 5.422

Review 6.  Regulation of activated T cell survival in rheumatic autoimmune diseases.

Authors:  Florencia Rosetti; Iris K Madera-Salcedo; Noé Rodríguez-Rodríguez; José C Crispín
Journal:  Nat Rev Rheumatol       Date:  2022-01-24       Impact factor: 32.286

7.  Genome-wide DNA methylation analysis in primary antiphospholipid syndrome neutrophils.

Authors:  Emma Weeding; Patrick Coit; Srilakshmi Yalavarthi; Mariana J Kaplan; Jason S Knight; Amr H Sawalha
Journal:  Clin Immunol       Date:  2018-11-22       Impact factor: 3.969

8.  Establishing a tree shrew model of systemic lupus erythematosus and cell transplantation treatment.

Authors:  Guang-Ping Ruan; Xiang Yao; Ju-Fen Liu; Jie He; Zi-An Li; Jian-Yong Yang; Rong-Qing Pang; Xing-Hua Pan
Journal:  Stem Cell Res Ther       Date:  2016-08-24       Impact factor: 6.832

9.  In Vivo Inhibition of MicroRNA-326 in a NOD.H-2h4 Mouse Model of Autoimmune Thyroiditis.

Authors:  Na Zhao; Zhenzhen Wang; Xuejiao Cui; Shuo Wang; Chenling Fan; Yushu Li; Zhongyan Shan; Weiping Teng
Journal:  Front Immunol       Date:  2021-06-01       Impact factor: 7.561

10.  Sex Differences in Correlation with Gene Expression Levels between Ifi200 Family Genes and Four Sets of Immune Disease-Relevant Genes.

Authors:  Yanhong Cao; Lishi Wang; Cong-Yi Wang; Jicheng Ye; Ying Wang; Tiantian Li; Franklin Garcia-Godoy; Dianjun Sun; Weikuan Gu; Arnold E Postlethwaite
Journal:  J Immunol Res       Date:  2018-08-28       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.